October 28, 2016 By Andy Cooper
A year ago, 3M’s Drug Delivery Systems, in partnership with Mylan, launched SirduplaTM in the UK as the first therapeutic equivalent to combination asthma therapy Seretide® Evohaler®. With that launch, 3M took an important step forward in the generics space. The partnership combined 3M’s expertise in inhalation drug development and manufacturing with Mylan’s leadership position in the global generics market.
3M has been filling, assembling and packaging Sirdupla at the Loughborough, UK manufacturing facility. By partnering with Mylan, 3M has once again proven that it is a worldwide leader in the inhalation space by putting its expertise of more than 60 years of inhalation drug development and manufacturing to work on another successful product launch.
To learn more about the development of the Sirdupla inhaler, please read Andy Cooper’s article, “A QbD Method Development Approach for a Generic pMDI” in the May 2016 issue of Pharmaceutical Technology.